Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Cytochroma opens US headquarters to direct expansion plans

Cytochroma : 30 April, 2008  (Company News)
Cytochroma has opened the compan’s US headquarters in Bannockburn, Illinois, located in the greater Chicago area at a site that will serve as the company's base for US commercial activities and for the expansion of its North American clinical and regulatory operations.
The expansion into the US will ensure that appropriate resources are available to support the company's numerous planned clinical programmes as well as subsequent US product launches.

Members of Cytochroma's current management team to be based in the Bannockburn office include Joel Z Melnick, MD, vice president of clinical and regulatory affairs and Eric J Messner, MBA, vice president of commercial operations. The company will retain and continue growing its existing corporate headquarters in Markham, Canada.

Charles W Bishop, PhD, president and chief executive officer, commented, 'This is an ideal time for Cytochroma to establish US operations, as we move our lead programmes into mid- to late-stage clinical trials and execute plans to develop our commercial infrastructure. The Chicago area is a prime location for Cytochroma, given the presence of a number of world-class pharmaceutical and healthcare companies focused on the chronic kidney disease market and the strong intellectual capital present in the region.'

Cytochroma has a diverse portfolio of Vitamin D-based therapeutics designed to treat disorders related to abnormal or insufficient Vitamin D metabolism in chronic kidney disease (CKD) patients. These new products will address target markets that are expected to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone.

Cytochroma has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo